Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability

Movement Disorders

Volumn 25, Issue 4, 2010, Pages 466-473

  Charles, P David ^a   Gill, Chandler E ^a   Taylor, Henry M ^b   Putman, Michael S ^a   Blair, CaraLee R ^a   Roberts, Amanda G ^a   Ayers, Gregory D ^a   Konrad, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Clover Bottom Developmental Center   (United States)

Author keywords

Activities of daily living; Developmental center; Direct care; Intellectual disability; Spasticity

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BRAIN HYPOXIA; CAREGIVER; CEREBRAL PALSY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRANIOFACIAL SYNOSTOSIS; DAILY LIFE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; INTELLECTUAL IMPAIRMENT; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANGE OF MOTION; SPASTICITY; VIDEOTAPE;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; BACLOFEN; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; COMORBIDITY; EPILEPSY; FEMALE; HEMIPLEGIA; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SPINAL; MALE; MENTAL RETARDATION; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PREVALENCE; VIDEOTAPE RECORDING;

EID: 77949537815     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22995     Document Type: Article

References (35)

1. Pfister AA, Roberts AG, Taylor HM, Noel-Spaudling S, Damian MM, Charles PD. Spasticity in adults living in a developmental center. Arch Phys Med Rehabil 2003;84:1808-1812.
2. Albright AL. Spasticity and movement disorders in cerebral palsy. J Child Neurol 1996;11(Suppl 1):S1-S4.
3. Engel JM, Jensen MP, Schwartz L. Outcome of biofeedbackassisted relaxation for pain in adults with cerebral palsy: preliminary findings. Appl Psychophysiol Biofeedback 2004;29:135-140.
4. Gooch JL, Oberg WA, Grams B, Ward LA, Walker ML. Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 2004;46:548-552.
5. Gormley ME, Jr., Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. Eur J Neurol 2001;8(Suppl 5): 127-135.
6. Jefferson RJ. Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 2004;46:491-499.
7. Krahn GL, Drum CE. Translating policy principles into practice to improve health care access for adults with intellectual disabilities: a research review of the past decade. Ment Retard Dev Disabil Res Rev 2007;13:160-168.
8. Ruddick L. Health of people with intellectual disabilities: a review of factors influencing access to health care. Br J Health Psychol 2005;10(Pt 4):559-570.
9. USDHHS. Closing the gap: a national blueprint to improve the health of persons with mental retardation. Report of the Surgeon General's Conference on Health Disparities and Mental Retardation 2002. Available at http://www.nichd.nih.gov/publications/pubs/closingthegap
10. Garrard SD. Health services for mentally retarded people in community residences: problems and questions. Am J Public Health 1982;72:1226-1228.
11. Minihan PM, Dean DH, Lyons CM. Managing the care of patients with mental retardation: a survey of physicians. Ment Retard 1993;31:239-246.
12. Nelson RP, Crocker AC. The medical care of mentally retarded persons in public residential facilities. N Engl J Med 9 1978;299: 1039-1044.
13. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000;83:481-487.
14. Sarioglu B, Serdaroglu G, Tutuncuoglu S, Ozer EA. The use of botulinum toxin type A treatment in children with spasticity. Pediatr Neurol 2003;29:299-301.
15. van Rhijn J, Molenaers G, Ceulemans B. Botulinum toxin type A in the treatment of children and adolescents with an acquired brain injury. Brain Inj 2005;19:331-335.
16. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002;83:1349-1354.
17. Platz T, Eickhof C, Nuyens G, Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 2005;27(1-2):7-18.
18. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil 2004;83(10 Suppl):S30-S37.
19. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-428.
20. Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev 2005;11:164-170.
21. ICI/UCEDD. Residential services for persons with developmental disabilities: status and trends through 2006. Research and Training Center on Community Living, University of Minnesota. 2007. Available at http://rtc.umn.edu/docs/risp2006.pdf
22. Weisstub DN, Arboleda-Florez J. Ethical research with the developmentally disabled. Can J Psychiatry 1997;42:492-496.
23. Freedman RI. Ethical challenges in the conduct of research involving persons with mental retardation. Ment Retard 2001;39:130-141.
24. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002;44:666-675.
25. Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Sleypen FA, Vles JS. Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study. Dev Med Child Neurol 2007;49:654-659.
26. Edwards SD. An argument against research on people with intellectual disabilities. Med Health Care Philos 2000;3:69-73.
27. Gill CE, Andrade EO, Blair CR, Taylor HM, Charles D. Combined treatment with BTX-A and ITB for spasticity: case report. Tenn Med 2007;100:41-42, 44.
28. Lannin N, Scheinberg A, Clark K. AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections. Dev Med Child Neurol 2006; 48:533-539.
29. Symons FJ, Rivard PF, Nugent AC, Tervo RC. Parent evaluation of spasticity treatment in cerebral palsy using botulinum toxin type A. Arch Phys Med Rehabil 2006;87:1658-1660.
30. Strauss D, Shavelle R, Reynolds R, Rosenbloom L, Day S. Survival in cerebral palsy in the last 20 years: signs of improvement? Dev Med Child Neurol 2007;49:86-92.
31. Hagood JS, Lenker CV, Thrasher S. A course on the transition to adult care of patients with childhood-onset chronic illnesses. Acad Med 2005;80:352-355.
32. Parker HW. Transition and transfer of patients who have cystic fibrosis to adult care. Clin Chest Med 2007;28:423-432.
33. Boyle MP, Farukhi Z, Nosky ML. Strategies for improving transition to adult cystic fibrosis care, based on patient and parent views. Pediatr Pulmonol 2001;32:428-436.
34. Reid GJ, Irvine MJ, McCrindle BW, et al. Prevalence and correlates of successful transfer from pediatric to adult health care among a cohort of young adults with complex congenital heart defects. Pediatrics 2004;113(3 Pt 1):e197-e205.
35. Banta JV. Tribulations of transition care for the developmentally disabled. Dev Med Child Neurol 2004;46:75.